Analyst consensus rating
Celldex Therapeutics Analyst Rating: Strong Buy
CLDX is rated Strong Buy by 15 analysts with a $58.07 target. As of 2026-08-19.
Direct answer
Celldex Therapeutics's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $58.07.
Forecast evidence checked August 19, 2026.
Get free Celldex Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $41.70
- Average price target
- $58.07
- High price target
- $100.00
- Low price target
- $38.00
- Low target gap
- -8.9%
- Target upside
- +39.2%
- High target gap
- +139.8%
- Target range width
- 148.7%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- August 19, 2026
- Valid through
- August 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Celldex Therapeutics?
Celldex Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $58.07.
How far are Celldex Therapeutics's low and high targets from the recorded price?
The low target implies -8.9%, while the high target implies +139.8%.
How many analysts are included in Celldex Therapeutics's consensus?
The verified consensus includes 15 analysts.
How is Celldex Therapeutics's target upside or downside calculated?
The average target of $58.07 is divided by the recorded price of $41.70, then one is subtracted to produce +39.2%. This does not guarantee a future return.
When was Celldex Therapeutics's analyst forecast verified?
The data was verified on 2026-08-19. The dataset is valid through 2026-08-26.